Welcome to our dedicated page for Summit Therapeutics SEC filings (Ticker: SMMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Summit Therapeutics Inc. (SMMT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. Summit is a Delaware-incorporated biopharmaceutical oncology company listed on The Nasdaq Stock Market LLC, and its filings offer detailed information on clinical progress, financing activities, and material agreements.
Among the key documents are Form 8-K current reports, where Summit has described material events such as private placements of common stock, amendments to its at-the-market distribution agreement, and clinical and scientific updates related to ivonescimab. For example, the company filed 8-Ks summarizing Akeso’s Phase III HARMONi-A results in EGFR-mutated NSCLC, including overall survival hazard ratios and median survival data for ivonescimab plus chemotherapy versus chemotherapy alone, and reporting presentations of HARMONi data at major oncology conferences.
Other 8-K filings detail Summit’s entry into securities purchase agreements for a significant private placement of common stock to institutional and individual investors, including insiders and Akeso, and amendments to its distribution agreement with a sales agent to expand its at-the-market equity offering capacity. Filings also cover operational matters such as a sub-sublease for office space in Palo Alto, California, and inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
Investors can also review references to Summit’s shelf registration on Form S-3 and related prospectus supplements that support its at-the-market program, as cited in the company’s 8-K disclosures. These filings help explain how Summit finances its global Phase III development program for ivonescimab and other corporate initiatives.
On Stock Titan, each new Summit filing is captured from EDGAR and paired with AI-powered summaries that highlight the main points, such as clinical trial outcomes, capital-raising terms, and key contractual provisions. Users can quickly understand the implications of a filing without reading the full legal text, while still having direct access to the original documents for deeper analysis.
Summit Therapeutics reported a sharply higher net loss and raised going concern doubts in its latest quarter. For the three months ended March 31, 2026, the company recorded a net loss of $189.4 million versus $62.9 million a year earlier, driven by intensive development spending on its lead cancer drug ivonescimab and a large increase in stock-based compensation.
Research and development expenses rose to $132.6 million, while general and administrative costs climbed to $62.6 million. Summit held $106.5 million in cash and cash equivalents and $492.2 million in short-term investments, which it states are insufficient to fund planned operations for at least one year, creating substantial doubt about its ability to continue as a going concern. The FDA has accepted the Biologics License Application for ivonescimab in EGFR-mutated lung cancer, with a Prescription Drug User Fee Act action date of November 14, 2026, but has indicated that a statistically significant overall survival benefit is necessary for potential approval.
Summit Therapeutics Inc. furnished an update on its first quarter ended March 31, 2026, reporting higher spending as it advances ivonescimab through multiple Phase III cancer trials and towards potential approval.
Aggregate cash, cash equivalents, and short-term investments were $598.7 million at March 31, 2026, down from $713.4 million at December 31, 2025, reflecting a quarterly cash burn with net cash used in operating activities of $122.3 million. GAAP operating expenses rose to $195.2 million from $66.8 million a year earlier, driven largely by higher stock-based compensation tied to modified performance-based awards.
GAAP net loss widened to $189.4 million, or $(0.24) per share, versus $62.9 million, or $(0.09), in the prior-year quarter, while non-GAAP net loss, excluding stock-based compensation, was $116.6 million, or $(0.15) per share. The company highlighted progress for ivonescimab, including an accepted Biologics License Application for the HARMONi NSCLC setting with a PDUFA goal date of November 14, 2026 and upcoming HARMONi-6 overall survival data to be featured in an ASCO 2026 Plenary Session.
Summit Therapeutics Inc. is asking stockholders to vote on four proposals at its 2026 virtual annual meeting on June 10, 2026. Items include electing nine directors, ratifying PricewaterhouseCoopers LLP as auditor, an advisory “say‑on‑pay” vote on executive compensation, and an amendment adding 8,000,000 shares to the 2020 Stock Incentive Plan. As of April 15, 2026, 776,079,959 common shares were outstanding and 388,039,981 must be represented to reach a quorum.
Summit Therapeutics Inc. is soliciting votes for its virtual 2026 Annual Meeting of Stockholders to be held via webcast on June 10, 2026 at 8:30 a.m. Eastern Daylight Time. Stockholders of record as of April 15, 2026 may vote.
Proposals include election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, a non-binding advisory vote on named executive officer compensation, and a request to amend the 2020 Stock Incentive Plan to add 8,000,000 shares to the plan. The Board unanimously recommends voting FOR all proposals.
Summit Therapeutics Inc. is a development-stage biopharmaceutical company focused on oncology, built around ivonescimab, a bispecific antibody targeting PD‑1 and VEGF-A. Summit has licensed rights to develop and commercialize ivonescimab across the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa under a collaboration with Akeso.
The company’s lead program is in non-small cell lung cancer, where the Phase III HARMONi trial in EGFR‑mutated patients previously treated with third‑generation EGFR TKIs showed a statistically significant progression‑free survival benefit for ivonescimab plus chemotherapy, with median PFS of 6.8 months versus 4.4 months for chemotherapy alone and a hazard ratio of 0.52. Longer follow‑up in Western patients confirmed a consistent PFS advantage.
Overall survival analyses showed a favorable trend, including in Western and North American subgroups, and supported submission of a Biologics License Application. The FDA has accepted the BLA for ivonescimab plus chemotherapy in this setting and plans a full review ahead of a Prescription Drug User Fee Act goal action date of November 14, 2026. Summit is also running additional Phase III trials in first‑line metastatic NSCLC (HARMONi‑3, HARMONi‑7) and first‑line unresectable metastatic colorectal cancer (HARMONi‑GI3), while Akeso advances multiple Phase II and III studies in other solid tumors. The company funds this strategy through a large upfront license cost, potential milestones and royalties owed to Akeso, and relies on third‑party manufacturing and extensive patent protection for ivonescimab through at least 2039.
Summit Therapeutics Inc. reported its fourth quarter and full-year 2025 results and outlined clinical progress centered on ivonescimab, its investigational bispecific PD‑1/VEGF antibody. For 2025, GAAP operating expenses rose to $1,094.4 million, driving a GAAP net loss of $1,079.6 million or $(1.44) per share, largely influenced by $732.4 million of stock-based compensation. On a Non-GAAP basis, operating expenses were $362.0 million and net loss was $347.2 million or $(0.46) per share. Cash, cash equivalents and short-term investments increased to $713.4 million as of December 31, 2025, supported by $617.5 million of financing cash inflows in 2025.
Clinically, the FDA accepted Summit’s Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC, assigning a PDUFA goal action date of November 14, 2026. Key Phase III milestones include an interim progression-free survival analysis for the HARMONi‑3 squamous cohort expected in Q2 2026, with final PFS and interim overall survival in the second half of 2026, and final PFS for the non‑squamous cohort expected in the first half of 2027. Summit also highlighted the planned Phase III ILLUMINE study in PD‑L1 positive head and neck cancer and multiple collaborations and investigator-sponsored trials expanding ivonescimab’s development footprint.
Summit Therapeutics Inc. reported that the U.S. Food & Drug Administration has accepted for filing its Biologics License Application for ivonescimab. The application seeks approval for ivonescimab combined with chemotherapy to treat patients with epidermal growth factor receptor‑mutated, locally advanced or metastatic non‑squamous non‑small cell lung cancer after tyrosine kinase inhibitor therapy.
The FDA set a Prescription Drug User Fee Act goal action date of November 14, 2026, which is the target date for completing its review. Summit disclosed this milestone via a press release, which is included as an exhibit.
Summit Therapeutics Inc. reported that its Chief Accounting Officer, Anand Bhaskar, received a stock option grant. On January 8, 2026, Bhaskar was awarded an option to purchase 30,000 shares of Summit Therapeutics common stock at an exercise price of $18.83 per share.
The option becomes exercisable over time, vesting in four equal annual installments, with the first installment scheduled to vest on January 8, 2027. The option expires on January 8, 2036. Following this grant, Bhaskar beneficially owns 30,000 derivative securities directly in the form of this stock option.
Summit Therapeutics Inc. reports a preliminary unaudited balance of approximately $710 million in cash, cash equivalents, and short-term investments as of December 31, 2025, providing a snapshot of its available liquidity.
The company also highlights key business developments: it plans to present at the 44th Annual J.P. Morgan Healthcare Conference, has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval for ivonescimab in combination with chemotherapy for certain epidermal growth factor receptor-mutated non-small cell lung cancer patients, and has entered into a clinical trial collaboration with GSK to study ivonescimab with GSK’s investigational B7-H3 targeting antibody drug conjugate across multiple solid tumors, including small cell lung cancer.